Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses
N. Valente
Advertisement
Articles by N. Valente
Relapsed or refractory low-grade non-Hodgkin’s lymphoma (NHL) and transformed low-grade NHL are incurable diseases. Tositumomab/iodine-131 tositumomab (Bexxar) is a novel
Advertisement
Latest Updated Articles
- Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data
Published: March 1st 2001 | Updated:
- Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions
Published: March 1st 2001 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
2
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
3
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
